Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Early Clinical Study to Evaluate the Safety and Efficacy of CLDN18.2 CAR T Cell Injection in Subjects With CLDN18.2-Positive Advanced Malignant Solid Tumors

NCT07680257 is registered in ClinicalTrials.gov with Celest Therapeutics (Shanghai) Co., Ltd. as lead sponsor.

NCT NCT07680257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07680257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Early Clinical Study to Evaluate the Safety and Efficacy of CLDN18.2 CAR T Cell Injection in Subjects With CLDN18.2-Positive Advanced Malignant Solid Tumors
Lead sponsor
Celest Therapeutics (Shanghai) Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
December 27, 2025
Completion date
December 31, 2028
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cldn18.2 positive solid tumors